Analysts See $-0.10 EPS for Immunomedics, Inc. (IMMU); Bellerophon Therapeutics (BLPH) SI Decreased By 40.36%

January 14, 2018 - By Nellie Frank

Bellerophon Therapeutics Incorporated (NASDAQ:BLPH) had a decrease of 40.36% in short interest. BLPH’s SI was 1.65M shares in January as released by FINRA. Its down 40.36% from 2.77 million shares previously. With 455,500 avg volume, 4 days are for Bellerophon Therapeutics Incorporated (NASDAQ:BLPH)’s short sellers to cover BLPH’s short positions. The SI to Bellerophon Therapeutics Incorporated’s float is 13.06%. The stock decreased 4.25% or $0.09 during the last trading session, reaching $2.03. About 148,648 shares traded. Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) has risen 23.81% since January 14, 2017 and is uptrending. It has outperformed by 7.11% the S&P500.

Analysts expect Immunomedics, Inc. (NASDAQ:IMMU) to report $-0.10 EPS on February, 8.They anticipate $0.06 EPS change or 37.50% from last quarter’s $-0.16 EPS. After having $-0.16 EPS previously, Immunomedics, Inc.’s analysts see -37.50% EPS growth. The stock increased 1.60% or $0.26 during the last trading session, reaching $16.51. About 2.27M shares traded. Immunomedics, Inc. (NASDAQ:IMMU) has risen 76.26% since January 14, 2017 and is uptrending. It has outperformed by 59.56% the S&P500.

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. The company has market cap of $112.02 million. The Company’s product candidates are INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis. It currently has negative earnings.

Among 3 analysts covering Immunomedics (NASDAQ:IMMU), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Immunomedics had 15 analyst reports since July 29, 2015 according to SRatingsIntel. On Friday, December 4 the stock rating was downgraded by Wells Fargo to “Market Perform”. Cowen & Co maintained Immunomedics, Inc. (NASDAQ:IMMU) rating on Wednesday, August 16. Cowen & Co has “Buy” rating and $15.0 target. The stock of Immunomedics, Inc. (NASDAQ:IMMU) earned “Buy” rating by Jefferies on Friday, May 6. Jefferies maintained it with “Buy” rating and $900 target in Friday, June 9 report. The firm has “Buy” rating given on Thursday, October 6 by Jefferies. The stock of Immunomedics, Inc. (NASDAQ:IMMU) earned “Buy” rating by Jefferies on Monday, October 9. Cowen & Co maintained the shares of IMMU in report on Wednesday, December 6 with “Buy” rating. The firm earned “Buy” rating on Tuesday, September 19 by Jefferies. As per Wednesday, December 6, the company rating was maintained by Jefferies. The firm has “Buy” rating given on Monday, July 24 by Cowen & Co.

Investors sentiment increased to 1.65 in 2017 Q3. Its up 0.24, from 1.41 in 2017Q2. It is positive, as 16 investors sold Immunomedics, Inc. shares while 36 reduced holdings. 38 funds opened positions while 48 raised stakes. 111.69 million shares or 33.14% more from 83.89 million shares in 2017Q2 were reported. Hanseatic Mngmt Services invested 0% in Immunomedics, Inc. (NASDAQ:IMMU). Ghost Tree Capital Llc, a New York-based fund reported 1.95 million shares. Sg Americas Ltd Limited Liability Company, New York-based fund reported 26,350 shares. Noven Group Inc accumulated 14,000 shares. Savings Bank Of Montreal Can accumulated 0% or 14,650 shares. Price T Rowe Assocs Inc Md holds 6.38 million shares. 161,000 were accumulated by Adage Cap Partners Group Inc Lc. Schwab Charles Inv Management has 0.01% invested in Immunomedics, Inc. (NASDAQ:IMMU). Suntrust Banks, Georgia-based fund reported 28,400 shares. Quantitative Inv Management Ltd Liability invested in 0% or 25,200 shares. California Employees Retirement owns 154,647 shares. Raymond James Serv Advsrs Inc owns 12,400 shares or 0% of their US portfolio. Lyon Street Capital Limited Liability reported 150,000 shares. Moreover, Northern Corp has 0% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 1.25 million shares. New York-based International Group Inc has invested 0% in Immunomedics, Inc. (NASDAQ:IMMU).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News